Frequently Asked Questions About XIENCE
Nonclinical testing has shown that the XIENCE Alpine stent, in single and in overlapped configurations up to 71 mm in length, can be safely scanned under the following conditions:*
- Static magnetic field of 1.5 or 3 Tesla
- Spatial gradient field of 2500 Gauss/cm or less
- Maximum whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode) for up to 15 minutes of scanning for each sequence
The XIENCE Alpine stent should not migrate in this MRI environment. MRI at 1.5 or 3 Tesla may be performed immediately post-implantation.
At the tested parameters noted above, the XIENCE Alpine stent produced a nonclinical maximum local temperature increase of 3.3°C. This does not take into consideration the cooling effects of blood flow.
An image artifact can be present, and MRI image quality may be compromised if the area of interest is at or near the stent position. Therefore, it may be necessary to optimize the MRI parameters to account for the presence of the XIENCE stent.
Refer to the IFU for Additional Information.
The XIENCE Alpine stent is available at lengths (mm) of:
8, 12, 15, 18, 23, 28, 33, 38
It is available in diameters (mm) of:
2.25, 2.5, 2.75, 3.0, 3.25, 3.5, 4.0
View ordering information here.
The specific fluoropolymer used—based on years of research—plays a critical role in XIENCE's superior outcomes. Abbott successfully identified a polymer that offers both mechanical integrity and scientific evidence of biocompatibility. Extensive research showed that polymers with a fluorinated surface were associated with “protective” attributes, such as the ability to tightly bind albumin to create a “protective cloak” around the stent.1-4 This results in the following characteristics, collectively known as fluoropassivation:
- Thromboresistance, referring to the preferential adsorption and retention of good protein (e.g., albumin) vs thrombogenic proteins (e.g., fibrinogen)—leading to less platelet adhesion and activation.1-4
- Minimal inflammatory response,1 since the preferential adsorption of albumin minimizes platelet adhesion, leukocyte activation and leukocyte recruitment.
- Functional healing, since preferential albumin adsorption elicits a cellular response conducive to healing, with rapid formation of functional endothelium and minimal chronic inflammation.1,5-6
Thus the XIENCE fluoropolymer was created to ensure long-term protection to the vessel and ultimately to the patient.
With more than 16,000 XIENCE patients involved in DAPT studies, Abbott has received a 1-month DAPT CE Label update. A study recently examined stent thrombosis (ST) and DAPT use through 2 years in a large pooled sample of patients from the XIENCE family of clinical studies.7 The study revealed that discontinuing DAPT:
- Before 1 month was strongly associated with ST
- After 3 months appeared safe
In addition, the STOPDAPT trial8 revealed 0% definite or probable ST with XIENCE when DAPT was discontinued at 3 months. Learn more about DAPT.